je.st
news
Tag: gilead sciences
Investment Firm Names Gilead Sciences, Inc.'s CEO Of 2014
2015-01-23 15:38:04| Auto Parts - Topix.net
Morningstar Names John Martin Of Gilead Sciences As Its 2014 CEO Of The Year CHICAGO, Jan. 21, 2015 /PRNewswire/ -- Morningstar, Inc. MORN, +2.87% a leading provider of independent investment research, today named John Martin of Gilead Sciences the recipient of its 2014 CEO of the Year award. Each year Morningstar recognizes a chief executive who exhibits commendable corporate stewardship, demonstrates independent thinking, creates lasting value for shareholders, and has put his or her stamp on an industry.
Tags: names
firm
investment
sciences
Aetna picks Gilead Sciences hepatitis C drugs over AbbVie's
2015-01-16 23:38:16| Biotech - Topix.net
Insurer Aetna has made new hepatitis C drugs from Gilead Sciences Inc. preferred treatments for customers with the liver-destroying virus. Aetna Inc. says it's reached a deal with Gilead bringing discounts for Sovaldi and Harvoni, which have list prices of about $84,000 and $94,000, respectively, for a course of treatment.
Tags: sciences
drugs
picks
hepatitis
Weekly CFO Sells Highlight: Coco-Cola Co, Gilead Sciences Inc, AutoZone Inc.
2014-12-15 10:25:01| Auto Parts - Topix.net
Executive VP, CFO Kathy N Waller sold 9,399 shares at an average price of $42. The price of the stock has decreased by 2.6% since.
Tags: inc
weekly
sciences
highlight
Gilead Sciences Inc. moving to new site in La Verne
2014-09-28 08:21:43| Biotech - Topix.net
Gilead Sciences Inc., a major pharmaceutical company, will establish a 23-acre campus in La Verne that will employ 500 people, extend Wheeler Avenue to Puddingstone Drive and conduct research for cures and improved treatment techniques for significant diseases. The scientific and medical research company committed to advancing therapeutics which improve lives will relocate from San Dimas to La Verne and take over a 23-acre parcel in the industrial and manufacturing zone in La Verne's southern quadrant, noted La Verne Senior Planner Eric Scherer during a recent La Verne City Council meeting.
Can Gilead Sciences Be A Do-Gooder And Still Do Well?
2014-09-27 15:18:50| Biotech - Topix.net
The top management of Wall Street highflier Gilead Sciences is facing a challenge that confronts many companies that have flourished but face the criticism that they need to give back to the global community in more direct ways. The fundamental question boils down to this: Can a company do well by doing good, for the sake of the world, and still do well - for its demanding stockholders? It's a major issue, as Gilead Science's stock has climbed about 40% so far this year, on the wings of the highly successful drug Sovaldi, which combats hepatitis C. The drug carries an enormous price tag of $1,000 per pill under a 12-week regimen that typically costs $84,000.